• 1
    Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003;361: 151160.
  • 2
    Braathen LR, Förre O, Natvig JB, Eeg-Larsen T. Predominance of T lymphocytes in the dermal infiltrate of atopic dermatitis. Br J Dermatol 1979;100: 511519.
  • 3
    Leung DYM, Bhan AK, Schneeberger EE, Geha RS. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 1983;71: 4756.
  • 4
    Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004;59: 561570.
  • 5
    Akdis CA, Akdis M, Simon D, Dibbert B, Weber M, Gratzl S et al. T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 1999;113: 628634.
  • 6
    Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94: 870876.
  • 7
    Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DYM. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98: 225231.
  • 8
    Grewe M, Gyufko K, Schopf E, Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;343: 2526.
  • 9
    Simon D, Borelli S, Braathen LR, Simon HU. Peripheral blood mononuclear cells from IgE and non-IgE associated allergic atopic eczema/dermatitis syndrome demonstrate increased capacity of generating IL-13 but differ in their potential of synthesizing interferon-γ. Allergy 2002;57: 431435.
  • 10
    Simon D, von Gunten S, Borelli S, Braathen LR, Simon H-U. Interleukin-13 production by peripheral blood T cells from extrinsic and intrinsic atopic dermatitis patients does not require CD2 co-stimulation. Int Arch Allergy Immunol 2003;132: 148155.
  • 11
    Marsland AM, Griffiths CEM. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002;12: 618622.
  • 12
    Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141: 264273.
  • 13
    Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stuetz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997;137: 568576.
  • 14
    Van Leent EJM, Graeber M, Thurston, M, Wagenaar A, Spuls P, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134: 805809.
  • 15
    Luger T, van Leent, EJM, Graeber M, Hedgecock S, Thurston M, Kandra A et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144: 788794.
  • 16
    Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989;144: 1314.
  • 17
    Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;92: S44S47.
  • 18
    Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10: 1118.
  • 19
    Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341: 11121120.
  • 20
    Simon HU, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-γ treatment in patients with corticosteroid-resistant asthma. Allergy 2003;58: 12501255.
  • 21
    Bieber T, Ring J, Braun-Falco O. Comparison of different methods for enumeration of Langerhans cells in vertical cryosections of human skin. Br J Dermatol 1988;118: 385392.
  • 22
    Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 2001;145: 720729.
  • 23
    Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113: 651657.
  • 24
    Kalthoff FS, Chung J, Stuetz A. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary activation by allogeneic dendritic cells. Clin Exp Immunol 2002;130: 8592.
  • 25
    Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000;9: 6977.
  • 26
    Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108: 275280.
  • 27
    Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004;114: 887895.
  • 28
    Mihm MC, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67: 305312.
  • 29
    Neckermann G, Bavandi A, Meingasser JG. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000;142: 669679.
  • 30
    Yawalkar N, Schmid S, Braathen LR, Pichler W. Perforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasis. Br J Dermatol 2001;144: 11331139.
  • 31
    Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000;106: 2535.
  • 32
    Saito H, Howie K, Wattie J, Denburg A, Ellis R, Inman MD et al. Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology 2001;104: 226234.
  • 33
    Akbar AN, Salmon M. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol Today 1997;18: 7276.
  • 34
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401: 708712.
  • 35
    Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106: 446453.
  • 36
    Ashworth J, Booker J, Breathnach SM. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br J Dermatol 1988;118: 457469.
  • 37
    Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Buerger A, Stuetz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003;149: 853857.
  • 38
    Kalthoff FS, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003;133: 350359.
  • 39
    Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004;122: 673684.